Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixekizumab - Eli Lilly and Company

X
Drug Profile

Ixekizumab - Eli Lilly and Company

Alternative Names: LY-2439821; Taltz

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; Oregon Health & Science University; Torii Pharmaceutical
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Erythrodermic psoriasis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Juvenile rheumatoid arthritis
  • Phase II Bullous pemphigoid; Pityriasis rubra pilaris; Pyoderma gangrenosum; Varicose ulcer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 May 2023 Efficacy data from a phase III trial in Ankylosing spondylitis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
  • 31 Dec 2022 Eli Lilly has data protection for ixekizumab in major European countries, until 2027
  • 31 Dec 2022 Eli Lilly has data protection for ixekizumab in Japan until 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top